Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.

被引：0
|
作者：
Massard, Christophe
Penttinen, Heidi
Bono, Petri
Vjaters, Egils
Lietuvietis, Vilnis
Tammela, Teuvo L. J.
Vuorela, Annamari
Nykanen, Pirjo
Pohjanjousi, Pasi
Fizazi, Karim
机构：
[1] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[2] Univ Helsinki, Cent Hosp, Ctr Canc, Helsinki, Finland
[3] P Stradins Clin Univ Hosp, Riga, Latvia
[4] Riga East Univ Hosp, Riga, Latvia
[5] Tampere Univ Hosp, Tampere, Finland
[6] Orion Corp Orion Pharma, Espoo, Finland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.230
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
230
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: A phase I/II, open-label study
    Dreicer, R.
    Agus, D. B.
    MacVicar, G. R.
    Wang, J.
    MacLean, D.
    Stadler, W. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Alejo Rodriguez-Vida
    Pablo Maroto
    Albert Font
    Cristina Martin
    Begoña Mellado
    Alex Corbera
    Mayra Orrillo
    Oscar Reig
    Rosa Querol
    Alejandro Rios-Hoyo
    Laia Cano
    Judith Alonso
    Gemma Martinez
    Susana Galtes
    Alvaro Taus
    Maria Martinez-Garcia
    Nuria Juanpere
    Oscar Juan
    Joaquim Bellmunt
    British Journal of Cancer, 2023, 128 : 21 - 29
  • [23] Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
    Rodriguez-Vida, Alejo
    Maroto, Pablo
    Font, Albert
    Martin, Cristina
    Mellado, Begona
    Corbera, Alex
    Orrillo, Mayra
    Reig, Oscar
    Querol, Rosa
    Rios-Hoyo, Alejandro
    Cano, Laia
    Alonso, Judith
    Martinez, Gemma
    Galtes, Susana
    Taus, Alvaro
    Martinez-Garcia, Maria
    Juanpere, Nuria
    Juan, Oscar
    Bellmunt, Joaquim
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 21 - 29
  • [24] The PREVAIL trial of enzalutamide in men with chemotherapy-naive, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
    Kim, Choung-Soo
    Theeuwes, Ad
    Kwon, Dong Deuk
    Choi, Young Deuk
    Chung, Byung Ha
    Lee, Hyun Moo
    Lee, Kang Hyun
    Lee, Sang Eun
    INVESTIGATIVE AND CLINICAL UROLOGY, 2016, 57 (03) : 174 - 183
  • [25] An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer
    Pezaro, Carmel
    Rosenthal, Mark A.
    Gurney, Howard
    Davis, Ian D.
    Underhill, Craig
    Boyer, Michael J.
    Kotasek, Dusan
    Solomon, Benjamin
    Toner, Guy C.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (04): : 338 - 341
  • [26] Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
    Nobuaki Matsubara
    Hirofumi Mukai
    Ako Hosono
    Mai Onomura
    Masaoki Sasaki
    Yoko Yajima
    Kensei Hashizume
    Masanobu Yasuda
    Miho Uemura
    Christian Zurth
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1073 - 1077
  • [27] Impact of Abiraterone Acetate and Enzalutamide on Symptom Burden of Patients with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Salem, S.
    Komisarenko, M.
    Timilshina, N.
    Martin, L.
    Grewal, R.
    Alibhai, S.
    Finelli, A.
    CLINICAL ONCOLOGY, 2017, 29 (09) : 601 - 608
  • [28] COST-EFFECTIVENESS ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN
    Okumura, H.
    Inoue, S.
    Naidoo, S.
    Holmstrom, S.
    Akaza, H.
    VALUE IN HEALTH, 2017, 20 (05) : A107 - A107
  • [29] Pharmacoeconomic aspects of using enzalutamide and abiraterone for treatment of chemotherapy-naive patients with metastatic castration-resistant prostate cancer
    Avxentyev, N. A.
    Frolov, M. Yu
    Makarova, Yu, V
    ONKOUROLOGIYA, 2019, 15 (02): : 86 - 99
  • [30] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Tagawa, Scott T.
    Ramaswamy, Krishnan
    Huang, Ahong
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Sandin, Rickard
    Lechpammer, Stanislav
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1032 - 1040
12345